PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

UCLA researchers engineer experimental drug for preventing heart failure after heart attacks

New single-dose therapy shows promise in enhancing repair after heart attacks in preclinical models

UCLA researchers engineer experimental drug for preventing heart failure after heart attacks
2024-10-24
(Press-News.org) Scientists at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have developed a first-of-its-kind experimental therapy that has the potential to enhance heart repair following a heart attack, preventing the onset of heart failure.

Cardiovascular disease continues to be the world’s leading cause of death, contributing to one-third of deaths annually. After a heart attack, the heart’s innate ability to regenerate is limited, causing the muscle to develop scars to maintain its structural integrity. This inflexible scar tissue, however, interferes with the heart’s ability to pump blood, leading to heart failure in many patients — 50% of whom do not survive beyond five years. The need for innovative therapies is urgent.

The new therapeutic approach aims to improve heart function after a heart attack by blocking a protein called ENPP1, which is responsible for increasing the inflammation and scar tissue formation that exacerbate heart damage. The findings, published in Cell Reports Medicine, could represent a major advance in post-heart attack treatment.

The research was led by senior author Dr. Arjun Deb, a professor of medicine and molecular, cell and developmental biology at UCLA.

“Despite the prevalence of heart attacks, therapeutic options have stagnated over the last few decades,” said Deb, who is also a member of the UCLA Broad Stem Cell Research Center. “There are currently no medications specifically designed to make the heart heal or repair better after a heart attack.”

The experimental therapy uses a therapeutic monoclonal antibody engineered by Deb and his team. This targeted drug therapy is designed to mimic human antibodies and inhibit the activity of ENPP1, which Deb had previously established increases in the aftermath of a heart attack.

The researchers found that a single dose of the antibody significantly enhanced heart repair in mice, preventing extensive tissue damage, reducing scar tissue formation and improving cardiac function. Four weeks after a simulated heart attack, only 5% of animals that received the antibody developed severe heart failure, compared with 52% of animals in the control group.

This therapeutic approach could become the first to directly enhance tissue repair in the heart following a heart attack; an advantage over current therapies that focus on preventing further damage but not actively promoting healing. This can be attributed to the way the antibody is designed to target cellular cross-talk, benefitting multiple cell types in the heart, including heart muscle cells, the endothelial cells that form blood vessels, and fibroblasts, which contribute to scar formation.

Initial findings from preclinical studies also show that the antibody therapy safely decreased scar tissue formation without increasing the risk of heart rupture — a common concern after a heart attack. However, Deb acknowledges that more work is needed to understand potential long-term effects of inhibiting ENPP1, including potential adverse effects on bone mass or bone calcification.

Deb’s team is now preparing to move this therapy into clinical trials. The team plans to submit an Investigational New Drug, or IND, application to the U.S. Food and Drug Administration this winter with the goal of beginning first-in-human studies in early 2025. These studies will be designed to administer a single dose of the drug in eligible individuals soon after a heart attack, helping the heart repair itself in the critical initial days after the cardiac event.

While the current focus is on heart repair after heart attacks, Deb’s team is also exploring the potential for this therapy to aid in the repair of other vital organs.

“The mechanisms of tissue repair are broadly conserved across organs, so we are examining how this therapeutic might help in other instances of tissue injury,” said Deb, who is also the director of the UCLA Cardiovascular Research Theme at the David Geffen School of Medicine. “Based on its effect on heart repair, this could represent a new class of tissue repair-enhancing drugs.”

The therapeutic candidate described in this study is covered by a patent held by the Regents of the University of California. The treatment strategy was used in preclinical tests only; it has not been tested in humans or approved by the FDA as safe and effective for use in humans.

Other UCLA authors include Shen Li, Bo Tao, Jijun Wan, Enca Montecino‐Rodriguez, Ping Wang, Baiming Sun,Yiqian Gu, Sivakumar Ramadoss, Lianjiu Su, Qihao Sun, Johanna Ten Hoeve, Linsey Stiles, Jeffrey Collins, R. Michael van Dam, Mikayla Tamboline, Richard Taschereau, Orian Shirihai, Matteo Pellegrini, Thomas Graeber, Kenneth Dorshkind and Shili Xu. Feiyang Ma of Northwestern University and Douglas B. Kitchen of Curia Global, Inc. contributed to the study.

The study received support from the National Institutes of Health, the California Institute for Regenerative Medicine and the Department of Defense.

END

[Attachments] See images for this press release:
UCLA researchers engineer experimental drug for preventing heart failure after heart attacks

ELSE PRESS RELEASES FROM THIS DATE:

Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer

Combining targeted therapy and immunotherapy improves overall survival in patients with anaplastic thyroid cancer
2024-10-24
HOUSTON ― Researchers from The University of Texas MD Anderson Cancer Center demonstrated that anti-PD-L1 immunotherapy in combination with mutation-directed targeted therapy extended overall survival (OS) in patients with anaplastic thyroid carcinoma (ATC). Findings from the Phase II single center study published today in JAMA Oncology.  The trial enrolled 42 patients across three cohorts to evaluate mutation-matched targeted therapy and the immune checkpoint inhibitor atezolizumab. The median OS across all cohorts was 19 months, which compares favorably to historical OS of five months for patients with ATC. ...

Assessing the real climate costs of manufacturing

2024-10-24
Producing materials such as steel, plastics and cement in the United States alone inflicts $79 billion a year in climate-related damage around the world, according to a new study by engineers and economists at the University of California, Davis. Accounting for these costs in market prices could encourage progress toward climate-friendly alternatives.  “We wanted to look at the cost to society to produce these materials,” said Elisabeth Van Roijen, a recent Ph.D. graduate from the UC Davis Department of Civil and Environmental Engineering ...

A multi-functional simulation platform for on-demand ride service operations

A multi-functional simulation platform for on-demand ride service operations
2024-10-24
On-demand ride services or ride-sourcing services have been experiencing fast development and steadily reshaping the way people travel in the past decade. Various optimization algorithms, including reinforcement learning approaches, have been developed to help ride-sourcing platforms design better operational strategies to achieve higher efficiency. However, due to cost and reliability issues, it is commonly infeasible to validate these models and train/test these optimization algorithms within real-world ride-sourcing platforms. Acting as a proper test bed, a simulation platform for ride-sourcing systems will thus be essential for both ...

Research team undertakes review of carbon anodes for lithium-ion batteries

Research team undertakes review of carbon anodes for lithium-ion batteries
2024-10-24
A team of researchers has undertaken a study of the future of carbon anodes for lithium-ion batteries. Their review provides a comprehensive overview of the progression in carbon anode development and the current status of their industrialization. This study underscores the critical role of interphase regulation engineering in advancing lithium-ion battery technology.   Their research is published in the journal Carbon Future on September 24, 2024.   Today, graphite is the most commonly used material for anodes in lithium-ion batteries. Graphite can operate at a low voltage, is readily available, and cost effective. While graphite materials ...

Researchers improve speed and accuracy of 3D surface measurements

Researchers improve speed and accuracy of 3D surface measurements
2024-10-24
WASHINGTON — Researchers have developed a faster and more accurate method for acquiring and reconstructing high-quality 3D surface measurements. The approach could greatly improve the speed and accuracy of surface measurements used for industrial inspection, medical applications, robotic vision and more. “Traditional 3D imaging works by comparing two viewpoints, similar to how our eyes work together to judge depth,” said research team leader Ce Zhu from the University of Electronic Science and Technology of China. “In contrast, our new approach ‘feels’ the surface by projecting light ...

GPX4 promoter hypermethylation induced by ischemia/reperfusion injury regulates hepatocytic ferroptosis

2024-10-24
Background and Aims Glutathione peroxidase 4 (GPX4) is a key factor in ferroptosis, which is involved in ischemia-reperfusion injury. However, little is known about its role in hepatic ischemia-reperfusion injury (HIRI). This study aimed to investigate the role of GPX4 methylation in ferroptosis during HIRI.   Methods For the in vivo experiments, an ischemia-reperfusion model was created by subjecting mice to simulated HIRI. Ferroptosis occurrence, GPX4 promoter methylation, and global methylation levels were then assessed.   Results Ferroptosis ...

Advances in biointegrated wearable and implantable optoelectronic devices for cardiac healthcare

Advances in biointegrated wearable and implantable optoelectronic devices for cardiac healthcare
2024-10-24
A review paper by scientists at Institute of Chemistry, Chinese Academy of Sciences summarized the progress of biointegrated flexible and stretchable optoelectronics for wearable and implantable cardiac healthcare. The new review paper, published on Oct. 18 in the journal Cyborg and Bionic Systems, focuses on the advances in biointegrated flexible and stretchable optoelectronics for wearable and implantable cardiac healthcare systems. With the prevalence of cardiovascular disease, it is imperative that medical monitoring and treatment become more instantaneous and comfortable for ...

Science/Science Careers’ survey ranks top biotech, biopharma, and pharma employers

2024-10-24
The Science and Science Careers’ 2024 Top Employers Survey polled employees in biotechnology, biopharmaceutical, pharmaceutical, and related industries to determine the 20 best employers as well as their driving characteristics. Respondents to the web-based survey were asked to rate companies based on 24 characteristics, including innovative leadership, respect for employees, and social responsibility. Insmed, Bridgewater, New Jersey, receives the top honor this year in a ranking of the world’s most respected employers. The rankings, determined from a study conducted by an independent research firm commissioned by the Science/AAAS Office of Publishing, ...

Belief in growth is key to becoming the best

2024-10-24
It takes a lot to succeed with ambitious goals. Among other things, we need passion and belief that we will succeed, and we usually need support from others. However, we also need to have the right attitude – the right mindset, one that makes us willing to do what it takes to change and improve. Experts refer to it as a growth mindset. So, how do we know if we actually have the right mindset? How can a coach know if a talented athlete has the mindset needed to become one of the best? An individual’s mindset is influenced by external factors that can change, and it may also vary from day to ...

Study finds intense exercise may suppress appetite in healthy humans

2024-10-24
WASHINGTON—A vigorous workout does more to suppress hunger levels in healthy adults than does moderate exercise, and females may be especially susceptible to this response, according to a small study published in the Journal of the Endocrine Society. The study examines the effects of exercise intensity on ghrelin levels and appetite between men and women. Ghrelin is known as the “hunger hormone” and is associated with perceptions of hunger. “We found that high intensity exercise suppressed ghrelin levels more than moderate intensity exercise,” said lead author Kara Anderson, Ph.D., of the University ...

LAST 30 PRESS RELEASES:

Call for papers: 14th Asia-Pacific Conference on Transportation and the Environment (APTE 2025)

A novel disturbance rejection optimal guidance method for enhancing precision landing performance of reusable rockets

New scan method unveils lung function secrets

Searching for hidden medieval stories from the island of the Sagas

Breakthrough study reveals bumetanide treatment restores early social communication in fragile X syndrome mouse model

Neuroscience leader reveals oxytocin's crucial role beyond the 'love hormone' label

Twelve questions to ask your doctor for better brain health in the new year

Microelectronics Science Research Centers to lead charge on next-generation designs and prototypes

Study identifies genetic cause for yellow nail syndrome

New drug to prevent migraine may start working right away

Good news for people with MS: COVID-19 infection not tied to worsening symptoms

Department of Energy announces $179 million for Microelectronics Science Research Centers

Human-related activities continue to threaten global climate and productivity

Public shows greater acceptance of RSV vaccine as vaccine hesitancy appears to have plateaued

Unraveling the power and influence of language

Gene editing tool reduces Alzheimer’s plaque precursor in mice

TNF inhibitors prevent complications in kids with Crohn's disease, recommended as first-line therapies

Twisted Edison: Bright, elliptically polarized incandescent light

Structural cell protein also directly regulates gene transcription

Breaking boundaries: Researchers isolate quantum coherence in classical light systems

Brain map clarifies neuronal connectivity behind motor function

Researchers find compromised indoor air in homes following Marshall Fire

Months after Colorado's Marshall Fire, residents of surviving homes reported health symptoms, poor air quality

Identification of chemical constituents and blood-absorbed components of Shenqi Fuzheng extract based on UPLC-triple-TOF/MS technology

'Glass fences' hinder Japanese female faculty in international research, study finds

Vector winds forecast by numerical weather prediction models still in need of optimization

New research identifies key cellular mechanism driving Alzheimer’s disease

Trends in buprenorphine dispensing among adolescents and young adults in the US

Emergency department physicians vary widely in their likelihood of hospitalizing a patient, even within the same facility

Firearm and motor vehicle pediatric deaths— intersections of age, sex, race, and ethnicity

[Press-News.org] UCLA researchers engineer experimental drug for preventing heart failure after heart attacks
New single-dose therapy shows promise in enhancing repair after heart attacks in preclinical models